And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...

Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

Indianapolis, Indiana Saturday, January 3, 2026, 10:00 Hrs [IST] ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis. News release. Elanco Animal Health. December 31, ...

A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...